These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
270 related articles for article (PubMed ID: 15661238)
21. Combining T-cell vaccination and application of agonistic anti-GITR mAb (DTA-1) induces complete eradication of HPV oncogene expressing tumors in mice. Hoffmann C; Stanke J; Kaufmann AM; Loddenkemper C; Schneider A; Cichon G J Immunother; 2010; 33(2):136-45. PubMed ID: 20145549 [TBL] [Abstract][Full Text] [Related]
22. Exploiting the plant secretory pathway to improve the anticancer activity of a plant-derived HPV16 E7 vaccine. Franconi R; Massa S; Illiano E; Mullar A; Cirilli A; Accardi L; Di Bonito P; Giorgi C; Venuti A Int J Immunopathol Pharmacol; 2006; 19(1):187-97. PubMed ID: 16569357 [TBL] [Abstract][Full Text] [Related]
23. Plasmid encoding papillomavirus Type 16 (HPV16) DNA constructed with codon optimization improved the immunogenicity against HPV infection. Cheung YK; Cheng SC; Sin FW; Xie Y Vaccine; 2004 Dec; 23(5):629-38. PubMed ID: 15542183 [TBL] [Abstract][Full Text] [Related]
24. Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation. Seo SH; Jin HT; Park SH; Youn JI; Sung YC Vaccine; 2009 Sep; 27(42):5906-12. PubMed ID: 19651174 [TBL] [Abstract][Full Text] [Related]
26. Prophylactic, therapeutic and anti-metastatic effects of an HPV-16mE6Delta/mE7/TBhsp70Delta fusion protein vaccine in an animal model. Qian X; Lu Y; Liu Q; Chen K; Zhao Q; Song J Immunol Lett; 2006 Feb; 102(2):191-201. PubMed ID: 16242781 [TBL] [Abstract][Full Text] [Related]
27. Mucosal immunisation with papillomavirus virus-like particles elicits systemic and mucosal immunity in mice. Liu XS; Abdul-Jabbar I; Qi YM; Frazer IH; Zhou J Virology; 1998 Dec; 252(1):39-45. PubMed ID: 9875315 [TBL] [Abstract][Full Text] [Related]
28. DNA vaccines against HPV-16 E7-expressing tumour cells. De Marco F; Hallez S; Brulet JM; Gesché F; Marzano P; Flamini S; Marcante ML; Venuti A Anticancer Res; 2003; 23(2B):1449-54. PubMed ID: 12820408 [TBL] [Abstract][Full Text] [Related]
29. Eradication of established HPV 16-expressing tumors by a single administration of a vaccine composed of a liposome-encapsulated CTL-T helper fusion peptide in a water-in-oil emulsion. Daftarian P; Mansour M; Benoit AC; Pohajdak B; Hoskin DW; Brown RG; Kast WM Vaccine; 2006 Jun; 24(24):5235-44. PubMed ID: 16675074 [TBL] [Abstract][Full Text] [Related]
32. Induction of human papilloma virus E6/E7-specific cytotoxic T-lymphocyte activity in immune-tolerant, E6/E7-transgenic mice. Riezebos-Brilman A; Regts J; Freyschmidt EJ; Dontje B; Wilschut J; Daemen T Gene Ther; 2005 Sep; 12(18):1410-4. PubMed ID: 15843807 [TBL] [Abstract][Full Text] [Related]
33. Chimeric hepatitis B core antigen particles containing B- and Th-epitopes of human papillomavirus type 16 E7 protein induce specific antibody and T-helper responses in immunised mice. Tindle RW; Herd K; Londoño P; Fernando GJ; Chatfield SN; Malcolm K; Dougan G Virology; 1994 May; 200(2):547-57. PubMed ID: 7513919 [TBL] [Abstract][Full Text] [Related]
34. Th2-type CD4+ cells neither enhance nor suppress antitumor CTL activity in a mouse tumor model. Fernando GJ; Stewart TJ; Tindle RW; Frazer IH J Immunol; 1998 Sep; 161(5):2421-7. PubMed ID: 9725239 [TBL] [Abstract][Full Text] [Related]
35. Mucosal vaccination with a recombinant Salmonella typhimurium expressing human papillomavirus type 16 (HPV16) L1 virus-like particles (VLPs) or HPV16 VLPs purified from insect cells inhibits the growth of HPV16-expressing tumor cells in mice. Revaz V; Benyacoub J; Kast WM; Schiller JT; De Grandi P; Nardelli-Haefliger D Virology; 2001 Jan; 279(1):354-60. PubMed ID: 11145916 [TBL] [Abstract][Full Text] [Related]
36. A novel therapeutic fusion protein vaccine by two different families of heat shock proteins linked with HPV16 E7 generates potent antitumor immunity and antiangiogenesis. Liu B; Ye D; Song X; Zhao X; Yi L; Song J; Zhang Z; Zhao Q Vaccine; 2008 Mar; 26(10):1387-96. PubMed ID: 18272260 [TBL] [Abstract][Full Text] [Related]
37. Comparison of DNA- and mRNA-transfected mouse dendritic cells as potential vaccines against the human papillomavirus type 16 associated oncoprotein E7. Dell K; Klein C; Gissmann L Antivir Ther; 2008; 13(4):495-509. PubMed ID: 18672528 [TBL] [Abstract][Full Text] [Related]
38. Chemically synthesized protein as tumour-specific vaccine: immunogenicity and efficacy of synthetic HPV16 E7 in the TC-1 mouse tumour model. Welters MJ; Filippov DV; van den Eeden SJ; Franken KL; Nouta J; Valentijn AR; van der Marel GA; Overkleeft HS; Lipford G; Offringa R; Melief CJ; van Boom JH; van der Burg SH; Drijfhout JW Vaccine; 2004 Dec; 23(3):305-11. PubMed ID: 15530672 [TBL] [Abstract][Full Text] [Related]
39. Generation of anti-tumor immunity using mammalian heat shock protein 70 DNA vaccines for cancer immunotherapy. Li Y; Subjeck J; Yang G; Repasky E; Wang XY Vaccine; 2006 Jun; 24(25):5360-70. PubMed ID: 16714072 [TBL] [Abstract][Full Text] [Related]
40. Enhancement of T cell-mediated and humoral immunity of beta-glucuronidase-based DNA vaccines against HPV16 E7 oncoprotein. Smahel M; Poláková I; Pokorná D; Ludvíková V; Dusková M; Vlasák J Int J Oncol; 2008 Jul; 33(1):93-101. PubMed ID: 18575754 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]